Intranasal Covid vaccine has not been under any trials as the other candidates of the Coronavirus vaccine. Serum Institute of India has started manufacturing a candidate for the intranasal Covid vaccine.
Manufacture the Intranasal Covid vaccine
There’s a vaccinated spray named Flumist nasal spray for the nose that helped to fight against influenza, but it is not a vaccine. Thus, the Serum Institute has started to manufacture Codagenix CDX 005 that will help to fight Sars-Cov-2 through this intranasal live attenuated vaccine candidate.
The trial study has already been completed in the animal bodies, and phase 1 clinical human trial will be done by the United Kingdom at the end of 2020.
Bharat Biotech has also agreed to conduct trials to produce and market the intranasal COVID vaccine. This agreement is with the Washington University School of medicine, as mentioned by Harsh Vardhan.
Will the COVID vaccines apply to the paediatric age group?
According to Harsh Vardhan, the Union Health Minister, Bharat Biotech’s candidate has undergone two trial phases, 1st one for the age group 18-55, while the 2nd phase was for 12-65. But as per the doctors, it is not possible to predict so soon that how the vaccines will work as the participants for phases 1 and 2 trials are in a too-small quantity.
The third trial will give a concrete result. Though the 1st and 2nd phases show promise during trials, and the third phase shows the rate of the performance. The 3rd phase will declare results on the age group of 18-99.
There are three candidates of COVID-vaccine ready after getting phase 1 and 2 trials, but there is no intranasal vaccine. That is the reason behind the manufacture of an intranasal vaccine to fight against coronavirus.
“Don’t have time to read? no problem. You can listen to our amazing podcasts here on the go.“